Natco Drug Discovery Private Limited

Natco Drug Discovery Private Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials and compliance.
CIN U24230TG1989PTC009942 Incorporated 02 May 1989 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Private Limited Company pharma
Data last updated
Revenue · FY 2026
₹4,078.3 Cr
▼ 7.93% YoY
EBITDA · FY 2026
₹1,734.1 Cr
▼ 32.01% YoY
Net profit · FY 2026
₹1,418.5 Cr
▼ 24.68% YoY
Authorised capital
₹5 Lakh
Registered with MCA
Paid-up capital
₹1.02 Lakh
Issued & subscribed
Open charges
None
Secured borrowings
Company age
37 yrs
Est. 1989
Last financials
Mar 2025
Balance sheet date

About Natco Drug Discovery Private Limited

Data last updated: 06 February 2026

Natco Drug Discovery Private Limited is a private limited company based in Hyderabad, Telangana, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 02 May 1989, the company has been in operation for over 37 years.

Registered with ROC Hyderabad under CIN U24230TG1989PTC009942.

Capital: an authorised share capital of ₹5 Lakh and a paid-up capital of ₹1.02 Lakh. Formerly known as Natchem Pharma Pvt Ltd. It is led by directors Sadasiva Rao Nannapaneni and Pathuri Srinivasa Rao.

Last AGM: 27 September 2025. Financial statements filed for year ended 31 March 2025. Office: Natco House Road No.2 Banjarahills, Hyderabad, Telangana, India – 500033.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website natcopharma.co.in.

Company Details of Natco Drug Discovery Private Limited
CIN U24230TG1989PTC009942
Registration Number 009942
Incorporation Date 02 May 1989
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Date of Last AGM 27 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Sadasiva Rao Nannapaneni Director Pathuri Srinivasa Rao Director
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    natcopharma.co.in
  • Social Media
    **************
  • Registered Address
    Natco House Road No.2 Banjarahills, Hyderabad, Telangana, India – 500033
  • Industry
    Pharma, Drug Formulation & Development
Company report
Natco Drug Discovery Private Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Natco Drug Discovery Private Limited report

Financials, compliance, directors, charges, ownership and filings for Natco Drug Discovery Private Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Natco Drug Discovery Private Limited

Natco Drug Discovery Private Limited has one previous CIN (Corporate Identification Number): U24230AP1989PTC009942. The current CIN is U24230TG1989PTC009942, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
U24230TG1989PTC009942 Current
U24230AP1989PTC009942 Previous

Business Activity of Natco Drug Discovery Private Limited

Natco Drug Discovery Private Limited operates primarily in the professional, scientific and technical sector. The company has 1 registered business activity segment, reflecting its diverse operational portfolio.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
********* Professional, Scientific and Technical ********* Scientific research and development *********

Auditor Details of Natco Drug Discovery Private Limited

Natco Drug Discovery Private Limited is audited by B S R and Co (ICAI peer reviewed, certificate valid till 2029-04-30) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
B S R and Co (ICAI peer reviewed, certificate valid till 2029-04-30) FY 2026 Declaration of unmodified opinion

Board of Directors of Natco Drug Discovery Private Limited

Natco Drug Discovery Private Limited is currently managed by 2 directors, with 2 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Sadasiva Rao Nannapaneni
Also directs: Time Cap Pharma Labs Private Limited, Ndl Infratech Private Limited, Natsoft Information Systems Private Limited and 2 more
Director 01 Jul 2016 10 Years 0 Months Current
Pathuri Srinivasa Rao Director 19 Jun 2002 24 Years 0 Months Current
View all directors

Financials of Natco Drug Discovery Private Limited FY 2026 filings available

Natco Drug Discovery Private Limited reported revenue of ₹4,078.3 Cr (down 7.93% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹4,078.3 Cr ▼ 7.93%
Profit · FY 2026
₹1,418.5 Cr ▼ 24.68%
EBITDA · FY 2026
₹1,734.1 Cr ▼ 32.01%
Revenue₹ Cr · Consolidated02,0004,0006,000FY 2020: ₹1,915 Cr1,915FY 2020FY 2021: ₹2,052 Cr · +7.2% YoY2,052+7.2%FY 2021FY 2022: ₹1,945 Cr · -5.2% YoY1,945-5.2%FY 2022FY 2023: ₹2,707 Cr · +39.2% YoY2,707+39.2%FY 2023FY 2024: ₹3,999 Cr · +47.7% YoY3,999+47.7%FY 2024FY 2025: ₹4,430 Cr · +10.8% YoY4,430+10.8%FY 2025FY 2026: ₹4,078 Cr · -7.9% YoY4,078-7.9%FY 2026
Net Profit₹ Cr · Consolidated01,0002,000FY 2020: ₹458 Cr458FY 2020FY 2021: ₹442 Cr · -3.4% YoY442-3.4%FY 2021FY 2022: ₹170 Cr · -61.6% YoY170-61.6%FY 2022FY 2023: ₹715 Cr · +320.8% YoY715+320.8%FY 2023FY 2024: ₹1,388 Cr · +94.1% YoY1,388+94.1%FY 2024FY 2025: ₹1,883 Cr · +35.7% YoY1,883+35.7%FY 2025FY 2026: ₹1,419 Cr · -24.7% YoY1,418-24.7%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year05001,0001,500Q1'25: ₹1,363 Cr · +19.5% YoY1,363+19.5%Q1'25Q2'25: ₹1,371 Cr · +32.9% YoY1,371+32.9%Q2'25Q3'25: ₹475 Cr · -37.4% YoY475-37.4%Q3'25Q4'25: ₹1,221 Cr · +14.3% YoY1,221+14.3%Q4'25Q1'26: ₹1,329 Cr · -2.5% YoY1,329-2.5%Q1'26Q2'26: ₹1,363 Cr · -0.6% YoY1,363-0.6%Q2'26Q3'26: ₹647 Cr · +36.3% YoY647+36.3%Q3'26Q4'26: ₹739 Cr · -39.5% YoY739-39.5%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹4,078.3 Cr ₹4,429.5 Cr ₹3,998.8 Cr ₹2,707.1 Cr ₹1,944.8 Cr ₹2,052.1 Cr ₹1,915 Cr
Other Income ₹297.6 Cr ₹354.5 Cr ₹128.1 Cr ₹104.6 Cr ₹99 Cr ₹103.6 Cr ₹107.4 Cr
Total Income ₹4,375.9 Cr ₹4,784 Cr ₹4,126.9 Cr ₹2,811.7 Cr ₹2,043.8 Cr ₹2,155.7 Cr ₹2,022.4 Cr
Cost of Materials Consumed ₹593.5 Cr ₹536.2 Cr ₹522.5 Cr ₹475.3 Cr ₹519.2 Cr ₹372.9 Cr ₹329 Cr
Purchases of Stock-in-Trade ₹203.2 Cr ₹166.1 Cr ₹151.4 Cr ₹175.7 Cr ₹58.5 Cr ₹186.6 Cr ₹127.8 Cr
Changes in Inventories -₹106.2 Cr -₹12.5 Cr ₹42.7 Cr -₹23.7 Cr -₹16.8 Cr -₹48.1 Cr -₹75.2 Cr
Employee Benefit Expense ₹687.2 Cr ₹594.5 Cr ₹525 Cr ₹486.7 Cr ₹444.8 Cr ₹414.9 Cr ₹375 Cr
Finance Costs ₹36.7 Cr ₹23.9 Cr ₹19.2 Cr ₹14.5 Cr ₹17.7 Cr ₹13.3 Cr ₹21.5 Cr
Depreciation & Amortisation ₹206.6 Cr ₹235.2 Cr ₹186.8 Cr ₹163.8 Cr ₹142.6 Cr ₹116.9 Cr ₹99.8 Cr
Other Expenses ₹1,264.1 Cr ₹949.2 Cr ₹1,005.8 Cr ₹657.5 Cr ₹675.6 Cr ₹519.6 Cr ₹575.8 Cr
Total Expenses ₹2,885.1 Cr ₹2,492.6 Cr ₹2,453.4 Cr ₹1,949.8 Cr ₹1,841.6 Cr ₹1,576.1 Cr ₹1,453.7 Cr
Profit Before Exceptional Items & Tax ₹1,490.8 Cr ₹2,291.4 Cr ₹1,673.5 Cr ₹861.9 Cr ₹202.2 Cr ₹579.6 Cr ₹568.7 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹1,490.8 Cr ₹2,291.4 Cr ₹1,673.5 Cr ₹861.9 Cr ₹202.2 Cr ₹579.6 Cr ₹568.7 Cr
Total Tax Expense ₹118.9 Cr ₹408 Cr ₹285.2 Cr ₹146.6 Cr ₹32.2 Cr ₹137.2 Cr ₹110.6 Cr
Net Profit ₹1,418.5 Cr ₹1,883.4 Cr ₹1,388.3 Cr ₹715.3 Cr ₹170 Cr ₹442.4 Cr ₹458.1 Cr
  attributable to Owners ₹1,418.5 Cr ₹1,885.4 Cr ₹1,388.3 Cr ₹715.3 Cr ₹170 Cr ₹440.9 Cr ₹460.8 Cr
  attributable to NCI ₹0 -₹2 Cr ₹0 ₹0 ₹0 ₹1.5 Cr -₹2.7 Cr
Other Comprehensive Income ₹287.4 Cr -₹24 Cr ₹14.9 Cr ₹2.7 Cr ₹49.7 Cr ₹8.7 Cr -₹14.5 Cr
Total Comprehensive Income ₹1,705.9 Cr ₹1,859.4 Cr ₹1,403.2 Cr ₹718 Cr ₹219.7 Cr ₹451.1 Cr ₹443.6 Cr
EBITDA (computed) ₹1,734.1 Cr ₹2,550.5 Cr ₹1,879.5 Cr ₹1,040.2 Cr ₹362.5 Cr ₹709.8 Cr ₹690 Cr
Basic EPS ₹79.20 ₹105.26 ₹77.34 ₹39.18 ₹9.32 ₹24.20 ₹25.33
Diluted EPS ₹79.20 ₹105.26 ₹77.34 ₹39.18 ₹9.32 ₹24.16 ₹25.26
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹11,074 Cr ₹8,630.8 Cr ₹6,906.3 Cr ₹5,657.4 Cr
Non-current Assets ₹6,021.4 Cr ₹3,360.8 Cr ₹2,882.8 Cr ₹2,657.1 Cr
Current Assets ₹5,052.3 Cr ₹5,270 Cr ₹4,023.5 Cr ₹3,000.3 Cr
Property, Plant & Equipment ₹2,545.4 Cr ₹2,431.9 Cr ₹2,297.7 Cr ₹2,239.1 Cr
Inventories ₹908.5 Cr ₹765.8 Cr ₹700.5 Cr ₹742.9 Cr
Trade Receivables ₹881.2 Cr ₹1,246.6 Cr ₹1,188.9 Cr ₹856.1 Cr
Cash & Equivalents ₹198.9 Cr ₹120 Cr ₹70.4 Cr ₹131.9 Cr
Equity (Net Worth) ₹9,221.1 Cr ₹7,612.3 Cr ₹5,853.1 Cr ₹4,873.8 Cr
Equity Share Capital ₹35.8 Cr ₹35.8 Cr ₹35.8 Cr ₹36.5 Cr
Borrowings (Non-current) ₹100 Cr ₹0 ₹0 ₹0
Borrowings (Current) ₹606.4 Cr ₹273.1 Cr ₹363.2 Cr ₹165 Cr
Total Debt (computed) ₹706.4 Cr ₹273.1 Cr ₹363.2 Cr ₹165 Cr
Current Liabilities ₹1,680.9 Cr ₹943.5 Cr ₹972.8 Cr ₹683.1 Cr
Total Liabilities ₹1,852.6 Cr ₹1,018.5 Cr ₹1,053.2 Cr ₹783.6 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹1,768.3 Cr ₹1,696.8 Cr ₹1,211.6 Cr ₹849.1 Cr ₹46.5 Cr
Investing Cash Flow -₹2,142.9 Cr -₹1,414.5 Cr -₹1,032.7 Cr -₹477.1 Cr -₹5.3 Cr
Financing Cash Flow ₹297.5 Cr -₹210.7 Cr -₹246.9 Cr -₹363 Cr ₹34.8 Cr
Capital Expenditure ₹388.3 Cr ₹401.1 Cr ₹339.4 Cr ₹146.3 Cr ₹232.7 Cr
Free Cash Flow (computed) ₹1,380 Cr ₹1,295.7 Cr ₹872.2 Cr ₹702.8 Cr -₹186.2 Cr
Dividends Paid ₹90.2 Cr ₹107.8 Cr ₹170.8 Cr ₹100.4 Cr ₹82.2 Cr
Net Change in Cash ₹78.9 Cr ₹49.6 Cr -₹61.5 Cr ₹20.8 Cr ₹85.3 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹739.1 Cr ₹647.3 Cr ₹1,363 Cr ₹1,328.9 Cr ₹1,221 Cr ₹474.8 Cr ₹1,371.1 Cr ₹1,362.6 Cr ₹1,068.3 Cr ₹758.6 Cr ₹1,031.4 Cr ₹1,140.5 Cr
Other Income ₹77.8 Cr ₹58.1 Cr ₹100 Cr ₹61.7 Cr ₹66.3 Cr ₹176.3 Cr ₹63.8 Cr ₹48.1 Cr ₹42 Cr ₹37 Cr ₹29.4 Cr ₹19.7 Cr
Total Income ₹816.9 Cr ₹705.4 Cr ₹1,463 Cr ₹1,390.6 Cr ₹1,287.3 Cr ₹651.1 Cr ₹1,434.9 Cr ₹1,410.7 Cr ₹1,110.3 Cr ₹795.6 Cr ₹1,060.8 Cr ₹1,160.2 Cr
Cost of Materials Consumed ₹102.8 Cr ₹135.2 Cr ₹174.9 Cr ₹180.6 Cr ₹169 Cr ₹72.7 Cr ₹143.2 Cr ₹151.3 Cr ₹127.6 Cr ₹92.2 Cr ₹166.5 Cr ₹136.2 Cr
Purchases of Stock-in-Trade ₹37.5 Cr ₹55.8 Cr ₹72.6 Cr ₹37.3 Cr ₹40.8 Cr ₹39.1 Cr ₹53.7 Cr ₹32.5 Cr ₹31.1 Cr ₹36.7 Cr ₹41 Cr ₹42.6 Cr
Changes in Inventories ₹14.4 Cr -₹57.9 Cr -₹77.8 Cr ₹15.1 Cr ₹39.4 Cr -₹29 Cr -₹19.3 Cr -₹3.6 Cr -₹16.1 Cr ₹33.3 Cr ₹8.3 Cr ₹17.2 Cr
Employee Benefit Expense ₹158.5 Cr ₹159.4 Cr ₹200.3 Cr ₹169 Cr ₹159.4 Cr ₹141.6 Cr ₹151.5 Cr ₹142 Cr ₹142.5 Cr ₹121.9 Cr ₹122.4 Cr ₹138.2 Cr
Finance Costs ₹10.9 Cr ₹9.5 Cr ₹13.1 Cr ₹3.2 Cr ₹10.2 Cr ₹4.4 Cr ₹4.1 Cr ₹5.2 Cr ₹6.2 Cr ₹4.6 Cr ₹4.2 Cr ₹4.2 Cr
Depreciation & Amortisation ₹50.4 Cr ₹46.2 Cr ₹52.4 Cr ₹57.6 Cr ₹98.3 Cr ₹47 Cr ₹45.8 Cr ₹44.1 Cr ₹55.5 Cr ₹44.2 Cr ₹43.6 Cr ₹43.5 Cr
Other Expenses ₹298.3 Cr ₹196.1 Cr ₹413.8 Cr ₹355.9 Cr ₹264.3 Cr ₹211.6 Cr ₹237.7 Cr ₹235.6 Cr ₹285.9 Cr ₹206.4 Cr ₹235.2 Cr ₹278.3 Cr
Total Expenses ₹672.8 Cr ₹544.3 Cr ₹849.3 Cr ₹818.7 Cr ₹781.4 Cr ₹487.4 Cr ₹616.7 Cr ₹607.1 Cr ₹632.7 Cr ₹539.3 Cr ₹621.2 Cr ₹660.2 Cr
Profit Before Exceptional Items & Tax ₹144.1 Cr ₹161.1 Cr ₹613.7 Cr ₹571.9 Cr ₹505.9 Cr ₹163.7 Cr ₹818.2 Cr ₹803.6 Cr ₹477.6 Cr ₹256.3 Cr ₹439.6 Cr ₹500 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹144.1 Cr ₹161.1 Cr ₹613.7 Cr ₹571.9 Cr ₹505.9 Cr ₹163.7 Cr ₹818.2 Cr ₹803.6 Cr ₹477.6 Cr ₹256.3 Cr ₹439.6 Cr ₹500 Cr
Total Tax Expense -₹89.2 Cr ₹20.7 Cr ₹95.8 Cr ₹91.6 Cr ₹99.9 Cr ₹31.3 Cr ₹141.7 Cr ₹135.1 Cr ₹91.3 Cr ₹43.6 Cr ₹70.6 Cr ₹79.7 Cr
Net Profit ₹269 Cr ₹151.3 Cr ₹517.9 Cr ₹480.3 Cr ₹406 Cr ₹132.4 Cr ₹676.5 Cr ₹668.5 Cr ₹386.3 Cr ₹212.7 Cr ₹369 Cr ₹420.3 Cr
  attributable to Owners ₹267.9 Cr ₹151.5 Cr ₹518.4 Cr ₹480.7 Cr ₹406.6 Cr ₹133 Cr ₹677.3 Cr ₹668.5 Cr ₹386.3 Cr ₹212.7 Cr ₹369 Cr ₹420.3 Cr
  attributable to NCI ₹1.1 Cr -₹20 Lakh -₹50 Lakh -₹40 Lakh -₹60 Lakh -₹60 Lakh -₹80 Lakh ₹0 ₹0 ₹0 ₹0 ₹0
Other Comprehensive Income ₹83.2 Cr ₹124.5 Cr ₹40.4 Cr ₹39.3 Cr -₹18.2 Cr -₹10.6 Cr ₹19.2 Cr -₹14.4 Cr -₹12.5 Cr ₹17.9 Cr -₹4.8 Cr ₹14.3 Cr
Total Comprehensive Income ₹352.2 Cr ₹275.8 Cr ₹558.3 Cr ₹519.6 Cr ₹387.8 Cr ₹121.8 Cr ₹695.7 Cr ₹654.1 Cr ₹373.8 Cr ₹230.6 Cr ₹364.2 Cr ₹434.6 Cr
EBITDA (computed) ₹205.4 Cr ₹216.8 Cr ₹679.2 Cr ₹632.7 Cr ₹614.4 Cr ₹215.1 Cr ₹868.1 Cr ₹852.9 Cr ₹539.3 Cr ₹305.1 Cr ₹487.4 Cr ₹547.7 Cr
Basic EPS ₹14.96 ₹8.46 ₹28.94 ₹26.84 ₹22.70 ₹7.43 ₹37.81 ₹37.32 ₹21.56 ₹11.88 ₹20.60 ₹23.26
Diluted EPS ₹14.96 ₹8.46 ₹28.94 ₹26.84 ₹22.70 ₹7.43 ₹37.81 ₹37.32 ₹21.56 ₹11.88 ₹20.60 ₹23.26
Latest 12 quarters shown of 25 on record.
Segment · Q4 FY26 (latest quarter) Revenue Result (PBIT) Assets Liabilities
Pharmaceuticals ₹716.5 Cr ₹155.4 Cr ₹9,675.9 Cr ₹1,491.3 Cr
Agro chemicals ₹22.6 Cr -₹40 Lakh ₹302.2 Cr ₹52 Cr
Segment · FY 2026 (annual) Revenue Result (PBIT) Assets Liabilities
Pharmaceuticals ₹3,940.1 Cr ₹1,547.3 Cr - -
Agro chemicals ₹138.2 Cr -₹19.8 Cr - -
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹3,594.6 Cr ₹4,094.5 Cr ₹3,568.9 Cr ₹2,351 Cr ₹1,767.8 Cr ₹1,653.5 Cr ₹1,790.2 Cr
Other Income ₹281.1 Cr ₹321.3 Cr ₹104.7 Cr ₹85.5 Cr ₹94.6 Cr ₹101.1 Cr ₹123.8 Cr
Total Income ₹3,875.7 Cr ₹4,415.8 Cr ₹3,673.6 Cr ₹2,436.5 Cr ₹1,862.4 Cr ₹1,754.6 Cr ₹1,914 Cr
Cost of Materials Consumed ₹593.5 Cr ₹536.2 Cr ₹522.5 Cr ₹475.3 Cr ₹519.2 Cr ₹372.9 Cr ₹329 Cr
Purchases of Stock-in-Trade ₹49.4 Cr ₹45.5 Cr ₹34.8 Cr ₹19.8 Cr ₹20.9 Cr ₹174 Cr ₹123.9 Cr
Changes in Inventories -₹69.2 Cr ₹11.6 Cr ₹17.2 Cr ₹34.6 Cr -₹5.5 Cr -₹46.9 Cr -₹55.9 Cr
Employee Benefit Expense ₹591.7 Cr ₹515.3 Cr ₹454.9 Cr ₹425.7 Cr ₹410.1 Cr ₹380 Cr ₹356.1 Cr
Finance Costs ₹32.3 Cr ₹19.6 Cr ₹14.5 Cr ₹8.6 Cr ₹13.3 Cr ₹11.3 Cr ₹20.6 Cr
Depreciation & Amortisation ₹189.6 Cr ₹220 Cr ₹171.9 Cr ₹150.9 Cr ₹138.4 Cr ₹115.2 Cr ₹98.1 Cr
Other Expenses ₹1,124.3 Cr ₹841.6 Cr ₹902.5 Cr ₹550.9 Cr ₹610.1 Cr ₹355.9 Cr ₹459.1 Cr
Total Expenses ₹2,511.6 Cr ₹2,189.8 Cr ₹2,118.3 Cr ₹1,665.8 Cr ₹1,706.5 Cr ₹1,362.4 Cr ₹1,330.9 Cr
Profit Before Exceptional Items & Tax ₹1,364.1 Cr ₹2,226 Cr ₹1,555.3 Cr ₹770.7 Cr ₹155.9 Cr ₹392.2 Cr ₹583.1 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹1,364.1 Cr ₹2,226 Cr ₹1,555.3 Cr ₹770.7 Cr ₹155.9 Cr ₹392.2 Cr ₹583.1 Cr
Total Tax Expense ₹82.6 Cr ₹375.6 Cr ₹248.7 Cr ₹133.6 Cr ₹16.8 Cr ₹82.7 Cr ₹108.6 Cr
Net Profit ₹1,281.5 Cr ₹1,850.4 Cr ₹1,306.6 Cr ₹637.1 Cr ₹139.1 Cr ₹309.5 Cr ₹474.5 Cr
Other Comprehensive Income ₹26.8 Cr -₹1.3 Cr ₹7.6 Cr -₹19.4 Cr ₹40.4 Cr ₹13.3 Cr -₹6.4 Cr
Total Comprehensive Income ₹1,308.3 Cr ₹1,849.1 Cr ₹1,314.2 Cr ₹617.7 Cr ₹179.5 Cr ₹322.8 Cr ₹468.1 Cr
EBITDA (computed) ₹1,586 Cr ₹2,465.6 Cr ₹1,741.7 Cr ₹930.2 Cr ₹307.6 Cr ₹518.7 Cr ₹701.8 Cr
Basic EPS ₹71.55 ₹103.31 ₹72.79 ₹34.90 ₹7.63 ₹16.99 ₹26.08
Diluted EPS ₹71.55 ₹103.31 ₹72.79 ₹34.90 ₹7.63 ₹16.96 ₹26.01
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹10,287 Cr ₹8,269.9 Cr ₹6,554 Cr ₹5,387.9 Cr
Non-current Assets ₹5,967.4 Cr ₹3,581.9 Cr ₹3,143.6 Cr ₹2,893.2 Cr
Current Assets ₹4,320 Cr ₹4,688 Cr ₹3,410.4 Cr ₹2,494.7 Cr
Property, Plant & Equipment ₹2,519.7 Cr ₹2,409.6 Cr ₹2,273.2 Cr ₹2,218.2 Cr
Inventories ₹723.6 Cr ₹642.1 Cr ₹596.9 Cr ₹616 Cr
Trade Receivables ₹759.6 Cr ₹1,178.2 Cr ₹1,076.6 Cr ₹793.1 Cr
Cash & Equivalents ₹11.5 Cr ₹11.2 Cr ₹5.5 Cr ₹6.9 Cr
Equity (Net Worth) ₹8,552.6 Cr ₹7,333.9 Cr ₹5,592.3 Cr ₹4,702 Cr
Equity Share Capital ₹35.8 Cr ₹35.8 Cr ₹35.8 Cr ₹36.5 Cr
Borrowings (Non-current) ₹100 Cr ₹0 ₹0 ₹0
Borrowings (Current) ₹606.4 Cr ₹273.1 Cr ₹363.2 Cr ₹159.9 Cr
Total Debt (computed) ₹706.4 Cr ₹273.1 Cr ₹363.2 Cr ₹159.9 Cr
Current Liabilities ₹1,566.4 Cr ₹864.6 Cr ₹885.6 Cr ₹569 Cr
Total Liabilities ₹1,734.8 Cr ₹936 Cr ₹961.7 Cr ₹685.9 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹1,776.4 Cr ₹1,662 Cr ₹1,196.4 Cr ₹799.8 Cr ₹57.7 Cr
Investing Cash Flow -₹2,078.2 Cr -₹1,443.9 Cr -₹960.5 Cr -₹436.6 Cr -₹92.5 Cr
Financing Cash Flow ₹302.1 Cr -₹212.4 Cr -₹237.3 Cr -₹345.4 Cr ₹35.6 Cr
Capital Expenditure ₹383.3 Cr ₹403.7 Cr ₹334.2 Cr ₹142.5 Cr ₹225.5 Cr
Free Cash Flow (computed) ₹1,393.1 Cr ₹1,258.3 Cr ₹862.2 Cr ₹657.3 Cr -₹167.8 Cr
Dividends Paid ₹90.2 Cr ₹107.8 Cr ₹170.8 Cr ₹100.4 Cr ₹82.1 Cr
Net Change in Cash ₹30 Lakh ₹5.7 Cr -₹1.4 Cr ₹17.8 Cr ₹80 Lakh
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹608.8 Cr ₹528.8 Cr ₹1,264.3 Cr ₹1,192.7 Cr ₹1,157.4 Cr ₹407.6 Cr ₹1,292.6 Cr ₹1,236.9 Cr ₹964.8 Cr ₹625.3 Cr ₹930.5 Cr ₹1,048.3 Cr
Other Income ₹72.9 Cr ₹55.3 Cr ₹93.3 Cr ₹59.6 Cr ₹62.1 Cr ₹168 Cr ₹51.4 Cr ₹39.8 Cr ₹35.9 Cr ₹29.5 Cr ₹24.7 Cr ₹14.6 Cr
Total Income ₹681.7 Cr ₹584.1 Cr ₹1,357.6 Cr ₹1,252.3 Cr ₹1,219.5 Cr ₹575.6 Cr ₹1,344 Cr ₹1,276.7 Cr ₹1,000.7 Cr ₹654.8 Cr ₹955.2 Cr ₹1,062.9 Cr
Cost of Materials Consumed ₹102.8 Cr ₹135.2 Cr ₹174.9 Cr ₹180.6 Cr ₹169 Cr ₹72.7 Cr ₹143.2 Cr ₹151.3 Cr ₹127.6 Cr ₹92.2 Cr ₹166.6 Cr ₹136.1 Cr
Purchases of Stock-in-Trade ₹13.3 Cr ₹7.6 Cr ₹20.6 Cr ₹7.9 Cr ₹9.7 Cr ₹14.8 Cr ₹13.3 Cr ₹7.7 Cr ₹8 Cr ₹11.1 Cr ₹6.8 Cr ₹8.9 Cr
Changes in Inventories ₹7.7 Cr -₹31.1 Cr -₹41 Cr -₹4.8 Cr ₹42.9 Cr -₹17.2 Cr -₹70 Lakh -₹13.4 Cr -₹29.7 Cr ₹7.4 Cr ₹7.5 Cr ₹32 Cr
Employee Benefit Expense ₹133.1 Cr ₹136.5 Cr ₹178.6 Cr ₹143.5 Cr ₹138.7 Cr ₹123.6 Cr ₹132.8 Cr ₹120.2 Cr ₹125 Cr ₹103.9 Cr ₹106.8 Cr ₹119.2 Cr
Finance Costs ₹9.7 Cr ₹8.3 Cr ₹11.7 Cr ₹2.6 Cr ₹8.8 Cr ₹3.4 Cr ₹3 Cr ₹4.4 Cr ₹4.5 Cr ₹3.8 Cr ₹3 Cr ₹3.2 Cr
Depreciation & Amortisation ₹45.6 Cr ₹42.1 Cr ₹48.1 Cr ₹53.8 Cr ₹93.7 Cr ₹43.7 Cr ₹42.2 Cr ₹40.4 Cr ₹51.6 Cr ₹40.4 Cr ₹40 Cr ₹39.9 Cr
Other Expenses ₹259.5 Cr ₹160.3 Cr ₹378.7 Cr ₹325.8 Cr ₹235.9 Cr ₹184.3 Cr ₹213.3 Cr ₹208.1 Cr ₹281.2 Cr ₹172.4 Cr ₹200.5 Cr ₹248.4 Cr
Total Expenses ₹571.7 Cr ₹458.9 Cr ₹771.6 Cr ₹709.4 Cr ₹698.7 Cr ₹425.3 Cr ₹547.1 Cr ₹518.7 Cr ₹568.2 Cr ₹431.2 Cr ₹531.2 Cr ₹587.7 Cr
Profit Before Exceptional Items & Tax ₹110 Cr ₹125.2 Cr ₹586 Cr ₹542.9 Cr ₹520.8 Cr ₹150.3 Cr ₹796.9 Cr ₹758 Cr ₹432.5 Cr ₹223.6 Cr ₹424 Cr ₹475.2 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹110 Cr ₹125.2 Cr ₹586 Cr ₹542.9 Cr ₹520.8 Cr ₹150.3 Cr ₹796.9 Cr ₹758 Cr ₹432.5 Cr ₹223.6 Cr ₹424 Cr ₹475.2 Cr
Total Tax Expense -₹99.6 Cr ₹18.3 Cr ₹85.1 Cr ₹78.8 Cr ₹92.7 Cr ₹25.4 Cr ₹135.8 Cr ₹121.7 Cr ₹83.4 Cr ₹31.6 Cr ₹63.8 Cr ₹69.9 Cr
Net Profit ₹209.6 Cr ₹106.9 Cr ₹500.9 Cr ₹464.1 Cr ₹428.1 Cr ₹124.9 Cr ₹661.1 Cr ₹636.3 Cr ₹349.1 Cr ₹192 Cr ₹360.2 Cr ₹405.3 Cr
Other Comprehensive Income ₹13.6 Cr ₹5.1 Cr ₹4.2 Cr ₹3.9 Cr -₹23.2 Cr ₹15.4 Cr ₹4.3 Cr ₹2.2 Cr -₹1.8 Cr ₹2.5 Cr ₹2.2 Cr ₹4.7 Cr
Total Comprehensive Income ₹223.2 Cr ₹112 Cr ₹505.1 Cr ₹468 Cr ₹404.9 Cr ₹140.3 Cr ₹665.4 Cr ₹638.5 Cr ₹347.3 Cr ₹194.5 Cr ₹362.4 Cr ₹410 Cr
EBITDA (computed) ₹165.3 Cr ₹175.6 Cr ₹645.8 Cr ₹599.3 Cr ₹623.3 Cr ₹197.4 Cr ₹842.1 Cr ₹802.8 Cr ₹488.6 Cr ₹267.8 Cr ₹467 Cr ₹518.3 Cr
Basic EPS ₹11.70 ₹5.97 ₹27.97 ₹25.91 ₹23.90 ₹6.97 ₹36.91 ₹35.53 ₹19.49 ₹10.72 ₹20.11 ₹22.43
Diluted EPS ₹11.70 ₹5.97 ₹27.97 ₹25.91 ₹23.90 ₹6.97 ₹36.91 ₹35.53 ₹19.49 ₹10.72 ₹20.11 ₹22.43
Latest 12 quarters shown of 25 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Natco Drug Discovery Private Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Natco Drug Discovery Private Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 49.42%, foreign institutional investors hold 17.37%, domestic institutional investors hold 5.46%, retail and other public shareholders hold 27.75% of Natco Drug Discovery Private Limited. The company had 410,970 shareholders on record.

Promoters: 49.42%DII (Domestic Institutional): 5.46%FII (Foreign Institutional): 17.37%Retail & Others: 27.75%
Mar 2026
QUARTER
49.42% Promoters
5.46% DII (Domestic Institutional)
17.37% FII (Foreign Institutional)
27.75% Retail & Others
Promoter holding - history
Now 49.42% · Mar 2026High 51.31% · Dec 2015Low 48.34% · Sep 2018
47%48.5%50%51.5%53%Dec 2015Jun 2018Dec 2020Jun 2023Dec 2025Dec 2015: 51.31%Mar 2016: 51.28%Jun 2016: 51.28%Sep 2016: 51.28%Dec 2016: 51.24%Mar 2017: 51.24%Jun 2017: 51.16%Sep 2017: 51.19%Dec 2017: 48.36%Mar 2018: 48.38%Jun 2018: 48.38%Sep 2018: 48.34%Dec 2018: 48.42%Mar 2019: 48.71%Jun 2019: 49.01%Sep 2019: 48.98%Dec 2019: 48.98%Mar 2020: 48.93%Jun 2020: 48.93%Sep 2020: 48.91%Dec 2020: 48.91%Mar 2021: 48.87%Jun 2021: 48.87%Sep 2021: 48.87%Dec 2021: 48.86%Mar 2022: 48.81%Jun 2022: 48.80%Sep 2022: 48.80%Dec 2022: 48.82%Mar 2023: 48.84%Jun 2023: 49.76%Sep 2023: 49.71%Dec 2023: 49.71%Mar 2024: 49.71%Jun 2024: 49.71%Sep 2024: 49.62%Dec 2024: 49.62%Mar 2025: 49.56%Jun 2025: 49.56%Sep 2025: 49.48%Dec 2025: 49.48%Mar 2026: 49.42%51.31%48.34%49.42%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters49.42%49.48%49.48%49.56%49.56%49.62%
Public50.58%50.52%50.52%50.44%50.44%50.38%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters49.42%49.56%49.71%48.84%48.81%48.87%48.93%48.71%48.38%51.24%51.28%
Public50.58%50.44%50.29%51.16%51.19%51.13%51.07%51.29%51.62%48.76%48.72%
Promoter change (YoY, %pts)-0.14-0.15+0.87+0.03-0.06-0.06+0.22+0.33-2.86-0.04-

Board & Governance of Natco Drug Discovery Private Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Natco Drug Discovery Private Limited has 9 directors - 5 independent and 4 executive. The board is chaired by VENKAIAH CHOWDARY NANNAPANENI.

DirectorPositionOn board sinceListed boards
VENKAIAH CHOWDARY NANNAPANENI Executive Director · MD · Chairperson 1981-09-19 1
RAJEEV NANNAPANENI Executive Director · CEO 2005-11-30 1
SIVARAMAKRISHNA PRASAD POTLURI Executive Director 2014-11-12 1
LINGARAO DONTHINENI Executive Director 2015-02-11 1
AGNIHOTRA DAKSHINA MURTY CHAVALI Non-Executive - Independent Director 2024-04-01 2
DRONADULA VIJAYA BHASKAR Non-Executive - Independent Director 2024-04-01 1
LAKSHMINARAYANA BOLISETTY Non-Executive - Independent Director 2024-08-12 3
SUMA KANTIPUDI Non-Executive - Independent Director 2024-08-12 1
NITIN JAIN Non-Executive - Independent Director 2024-08-12 2
Board Committees
CommitteeMembers
Audit Committee AGNIHOTRA DAKSHINA MURTY CHAVALI, DRONADULA VIJAYA BHASKAR, LAKSHMINARAYANA BOLISETTY (Chairperson), NITIN JAIN
Nomination and remuneration committee DRONADULA VIJAYA BHASKAR (Chairperson), AGNIHOTRA DAKSHINA MURTY CHAVALI, LAKSHMINARAYANA BOLISETTY, SUMA KANTIPUDI
Stakeholders Relationship Committee VENKAIAH CHOWDARY NANNAPANENI, RAJEEV NANNAPANENI, DRONADULA VIJAYA BHASKAR (Chairperson), NITIN JAIN
Risk Management Committee VENKAIAH CHOWDARY NANNAPANENI (Chairperson), RAJEEV NANNAPANENI, SIVARAMAKRISHNA PRASAD POTLURI, LINGARAO DONTHINENI, LAKSHMINARAYANA BOLISETTY, A LAKSHMINARAYANA, AMIT PAREKH, BHIMRAO DATTU JADHAV, DR SRIRAM RAMPALLI, VEERA VENKATA NARASIMHA APPA RAO SANNIDHANAM
Corporate Social Responsibility Committee VENKAIAH CHOWDARY NANNAPANENI (Chairperson), RAJEEV NANNAPANENI, DRONADULA VIJAYA BHASKAR, SUMA KANTIPUDI

Charges & Borrowings Natco Drug Discovery Private Limited

Natco Drug Discovery Private Limited does not have any charges (loans) registered with the Registrar of Companies.

Employees and EPFO Compliance at Natco Drug Discovery Private Limited

View historical data on people associated with Natco Drug Discovery Private Limited, including employment history and EPFO contributions.

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Natco Drug Discovery Private Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Natco Drug Discovery Private Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Natco Drug Discovery Private Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Natco Drug Discovery Private Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Natco Drug Discovery Private Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Natco Drug Discovery Private Limited

MSME Payment Delays by Natco Drug Discovery Private Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Natco Drug Discovery Private Limited

Subsidiaries & Group Companies of Natco Drug Discovery Private Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Natco Drug Discovery Private Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Natco Drug Discovery Private Limited

MCA Filings & Documents of Natco Drug Discovery Private Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Natco Drug Discovery Private Limited

Activity
27 Sep 2025
Natco Drug Discovery Private Limited last Annual general meeting of members was held on 27 Sep 2025 as per latest MCA records.
Activity
31 Mar 2025
Natco Drug Discovery Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Directors
01 Jul 2016
Sadasiva Rao Nannapaneni was appointed as a Director on 01 Jul 2016 & has been associated with this company since 10 years 8 days.
Directors
19 Jun 2002
Pathuri Srinivasa Rao was appointed as a Director on 19 Jun 2002 & has been associated with this company since 24 years 20 days.
Activity
02 May 1989
Natco Drug Discovery Private Limited was registered on 02 May 1989 with Roc Hyderabad & aged 37 years 2 months as per MCA records.

Recent News on Natco Drug Discovery Private Limited

Frequently Asked Questions about Natco Drug Discovery Private Limited

Natco Drug Discovery Private Limited is an active private limited company in the pharma sector based in Hyderabad, Telangana, India. It was incorporated on 02 May 1989 (37+ years old) and is registered under CIN U24230TG1989PTC009942.

The current directors of Natco Drug Discovery Private Limited are:

The primary industry of Natco Drug Discovery Private Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Natco Drug Discovery Private Limited can be reached at the registered office: Natco House Road No.2 Banjarahills, Hyderabad, Telangana, India – 500033, or through the website natcopharma.co.in.

The authorised capital is ₹5 Lakh, and the paid-up capital is ₹1.02 Lakh.

The company has its registered office at Natco House Road No.2 Banjarahills, Hyderabad, Telangana, India – 500033.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available